Preservation of endothelium-dependent relaxation in cholesterol-fed and streptozotocin-induced diabetic mice by the chronic administration of cholestyramine
被引:30
作者:
Kamata, K
论文数: 0引用数: 0
h-index: 0
机构:Dept. of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku
Kamata, K
Sugiura, M
论文数: 0引用数: 0
h-index: 0
机构:Dept. of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku
Sugiura, M
Kojima, S
论文数: 0引用数: 0
h-index: 0
机构:Dept. of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku
Kojima, S
Kasuya, Y
论文数: 0引用数: 0
h-index: 0
机构:Dept. of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku
Kasuya, Y
机构:
[1] Dept. of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku
1 Experiments were designed to investigate the effects of the low density lipoprotein (LDL)-lowering drugs cholestyramine on serum LDL levels and endothelium-dependent relaxation to acetylcholine (ACh) in cholesterol-fed or streptozotocin (STZ)-induced diabetic mice. 2 In aortic rings from control mice, ACh or A23187 caused concentration-dependent relaxation. The relaxations caused by ACh or A23187 were significantly attenuated in aortic rings from cholesterol-fed and STZ-diabetic mice. The attenuated vasodilatation in both cholesterol-fed and diabetic mice was returned to normal by chronic administration of cholestyramine. The endothelium-independent relaxations of aortic rings induced by sodium nitroprusside (SNP) were not significantly different between control, cholesterol-fed and STZ-induced diabetic mice. 3 The increased LDL levels in cholesterol-fed and diabetic mice were returned to normal by the chronic administration of cholestyramine. Chronic administration of cholestyramine had no effects on serum glucose levels. 4 These results suggest that attenuated endothelium-dependent vasodilatations in both cholesterol-fed and STZ-diabetic mice are improved by the chronic administration of cholestyramine, and these effects are, at least in part, due to lowering serum LDL levels.